HC Wainwright & Co. reiterated coverage on Balchem with a new price target
$BCPC
Major Chemicals
Industrials
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Get the next $BCPC alert in real time by email
Get the next $BCPC alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $BCPC
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
Balchem Corporation to Participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025
MONTVALE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the BNP Paribas Exane 13th Consumer Ingredients Conference on March 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solu
Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025
MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87
HC Wainwright & Co. reiterated coverage on Balchem with a new price target
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Balchem upgraded by Sidoti with a new price target
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
HC Wainwright & Co. reiterated coverage on Balchem with a new price target
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
SVP and GM, Specialty Products Van Gunsteren Job Leonard was granted 2,128 shares and covered exercise/tax liability with 964 shares, increasing direct ownership by 14% to 9,446 units (SEC Form 4)
4 - BALCHEM CORP (0000009326) (Issuer)
SVP Chief Supply Chain Officer Reid Martin Luther was granted 3,889 shares and covered exercise/tax liability with 1,059 shares, increasing direct ownership by 49% to 8,591 units (SEC Form 4)
4 - BALCHEM CORP (0000009326) (Issuer)
SVP & Chief HR Officer Tignor Michael Brent was granted 3,497 shares and covered exercise/tax liability with 1,156 shares, increasing direct ownership by 35% to 9,123 units (SEC Form 4)
4 - BALCHEM CORP (0000009326) (Issuer)
Balchem Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - BALCHEM CORP (0000009326) (Filer)
SEC Form 10-K filed by Balchem Corporation
10-K - BALCHEM CORP (0000009326) (Filer)
Balchem Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BALCHEM CORP (0000009326) (Filer)
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
Balchem Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:
Balchem Corporation Announces Quarterly Conference Call for Fourth Quarter and Full Year 2024 Financial Results on February 21, 2025
MONTVALE, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 21, 2025, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2024 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year results will be published prior to the market opening on Friday, February 21, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-87
Balchem Corporation Announces Dividend
MONTVALE, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that on December 9, 2024, its Board of Directors declared a dividend on its shares of common stock equal to $0.87 per share on the Company's issued and outstanding Common Stock, to be payable on January 17, 2025 to stockholders of record at the close of business on December 26, 2024. This dividend represents an 10.1% increase over last year's annual dividend. Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the sixteenth consecuti
Amendment: SEC Form SC 13G/A filed by Balchem Corporation
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SEC Form SC 13G/A filed by Balchem Corporation (Amendment)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SEC Form SC 13G/A filed by Balchem Corporation (Amendment)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)